Aethlon Medical Files 8-K for Material Agreement

TL;DR

AEMD signed a material definitive agreement on 9/4/25, details to follow.

AI Summary

Aethlon Medical, Inc. (AEMD) filed an 8-K on September 9, 2025, reporting a material definitive agreement entered into on September 4, 2025. The filing also includes other events and financial statements/exhibits. Specific details of the material agreement are not provided in this excerpt.

Why It Matters

This filing indicates a significant new contract or partnership for Aethlon Medical, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, but the lack of specific details about the agreement introduces uncertainty.

Key Players & Entities

• Aethlon Medical, Inc. (company) — Registrant
• 0001683168-25-006788 (filing_id) — Accession Number
• September 4, 2025 (date) — Date of earliest event reported
• September 9, 2025 (date) — Date of report
• Nevada (jurisdiction) — State of incorporation
• 001-37487 (file_number) — SEC File Number
• 13-3632859 (ein) — IRS Employer Identification No.
• 11555 Sorrento Valley Road, Suite 203 (address) — Principal executive offices
• San Diego, California (location) — Principal executive offices city and state
• 92121 (zip_code) — Principal executive offices zip code

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share AEMD The Nasdaq
• $0.90 — at a combined public offering price of $0.90 per Common Unit. The Common Warrants a
• $281,250 — proceeds of the Offering (amounting to $281,250) at closing, as well as $100,000 for th
• $100,000 — ing to $281,250) at closing, as well as $100,000 for the reimbursement of certain of the
• $4.5 m — ved gross proceeds from the Offering of $4.5 million, before deducting Placement Agent
• $3.9 million — ent Agent Warrants), were approximately $3.9 million. The Company intends to use the net pro

Filing Documents

• aemd_8k.htm (8-K) — 35KB
• aethlon_ex0401.htm (EX-4.1) — 131KB
• aethlon_ex0402.htm (EX-4.2) — 90KB
• aethlon_ex0403.htm (EX-4.3) — 130KB
• aethlon_ex1001.htm (EX-10.1) — 209KB
• aethlon_ex1002.htm (EX-10.2) — 60KB
• aethlon_ex9901.htm (EX-99.1) — 14KB
• aemdlogo.jpg (GRAPHIC) — 6KB
• image_012.jpg (GRAPHIC) — 4KB
• 0001683168-25-006788.txt ( ) — 989KB
• aemd-20250904.xsd (EX-101.SCH) — 3KB
• aemd-20250904_lab.xml (EX-101.LAB) — 33KB
• aemd-20250904_pre.xml (EX-101.PRE) — 22KB
• aemd_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On September 4, 2025, the Company issued a press release regarding the pricing of the Offering. A copy of the press release is furnished as Exhibit 99.1 hereto and incorporated by reference.

01 Financial Statements

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 4.1 Form of Common Warrant, dated September 4, 2025 . 4.2 Form of Pre-Funded Warrant, dated September 4, 2025 . 4.3 Placement Agent Warrant, dated September 4, 2025 . 4.4 Form of Warrant Agency Agreement by and between Aethlon Medical, Inc. and Computershare Inc. and its affiliate, Computershare Trust Company, N.A. (incorporated by reference to Form S-1/A filed on August 29, 2025 as Exhibit 4.13) 10.1 Form of Securities Purchase Agreement, dated September 4, 2025, by and between Aethlon Medical, Inc. and investors party thereto . 10.2 Placement Agency Agreement, dated September 4, 2025 by and between Aethlon Medical, Inc. and Maxim Group, LLC . 99.1 Press Release, dated September 4, 2025 . 104 Cover Page Interactive Data File (embedded within the inline XBRL Document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 9, 2025 Aethlon Medical, Inc. By: /s/ James B. Frakes Name: James B. Frakes Chief Executive Officer and Chief Financial Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR